Influenza activity and vaccine composition for the 2022-23 Northern Hemisphere season in the US

A report provides information on influenza activity and the composition of the Northern Hemisphere 2022-23 influenza vaccine in the United States. The specific study design, population, sample size, and follow-up duration are not reported. The intervention or exposure and any comparator are also not reported. No primary or secondary outcomes, main results, or numerical data are provided in the available evidence. Safety and tolerability information, including adverse events and discontinuations, is not reported. Key limitations, such as the study methodology and potential for bias, are not described. The funding sources and any author conflicts of interest are not reported. The practice relevance and any causal implications are not specified. Given the lack of detailed methodology and results, this report should be viewed as a general descriptive update rather than a source of clinical evidence for decision-making.